Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BCDA NASDAQ:BLRX NASDAQ:DCOY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.73-0.3%$1.58$1.26▼$4.50$12.54M2.29468,261 shs2,946 shsBCDABioCardia$1.13+2.3%$1.20$1.00▼$2.92$12.31M0.5665,837 shs4,286 shsBLRXBioLineRx$3.43+12.9%$2.52$2.15▼$7.77$14.92M1.4217,618 shs55,633 shsDCOYDecoy Therapeutics$5.77-1.2%$6.83$5.15▼$415.80$3.09M0.38141,868 shs3,145 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.58%-3.89%+20.14%-15.20%-37.09%BCDABioCardia-0.90%-3.51%-8.33%+0.92%-56.00%BLRXBioLineRx+6.29%+15.59%+37.56%-0.98%-6.46%DCOYDecoy Therapeutics-1.10%+6.76%+0.69%-22.75%+583,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.73-0.3%$1.58$1.26▼$4.50$12.54M2.29468,261 shs2,946 shsBCDABioCardia$1.13+2.3%$1.20$1.00▼$2.92$12.31M0.5665,837 shs4,286 shsBLRXBioLineRx$3.43+12.9%$2.52$2.15▼$7.77$14.92M1.4217,618 shs55,633 shsDCOYDecoy Therapeutics$5.77-1.2%$6.83$5.15▼$415.80$3.09M0.38141,868 shs3,145 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.58%-3.89%+20.14%-15.20%-37.09%BCDABioCardia-0.90%-3.51%-8.33%+0.92%-56.00%BLRXBioLineRx+6.29%+15.59%+37.56%-0.98%-6.46%DCOYDecoy Therapeutics-1.10%+6.76%+0.69%-22.75%+583,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/ABCDABioCardia 2.00Hold$25.002,122.22% UpsideBLRXBioLineRx 2.67Moderate BuyN/AN/ADCOYDecoy Therapeutics 2.00Hold$30.00419.75% UpsideCurrent Analyst Ratings BreakdownLatest DCOY, AIMD, BLRX, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/20/2026BCDABioCardia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K104.51N/AN/A$1.29 per share1.34BCDABioCardia$60K205.13N/AN/A$0.08 per share14.06BLRXBioLineRx$1.18M12.66N/AN/A$5.36 per share0.64DCOYDecoy TherapeuticsN/AN/AN/AN/A$11.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$3.53N/AN/AN/A-11,912.10%-140.10%-62.97%5/11/2026 (Estimated)BCDABioCardia-$8.23M-$1.29N/AN/AN/AN/A-28,372.40%-238.22%5/13/2026 (Estimated)BLRXBioLineRx-$1.17M-$0.17N/AN/AN/A-99.58%-5.61%-2.81%5/26/2026 (Estimated)DCOYDecoy Therapeutics-$12.52M-$406.89N/AN/AN/AN/A-534.45%-239.74%N/ALatest DCOY, AIMD, BLRX, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/26/2026Q1 2026BLRXBioLineRx-$1.04N/AN/AN/A$0.34 millionN/A5/13/2026Q1 2026BCDABioCardia-$0.17N/AN/AN/AN/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/A$0.01 million3/24/2026Q4 2025BCDABioCardia-$0.20-$0.06+$0.14-$0.06$0.03 millionN/A3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.451.060.78BCDABioCardiaN/A1.121.12BLRXBioLineRx0.191.951.78DCOYDecoy TherapeuticsN/A2.132.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABCDABioCardia20.57%BLRXBioLineRx1.56%DCOYDecoy Therapeutics11.88%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%BCDABioCardia17.40%BLRXBioLineRx1.10%DCOYDecoy Therapeutics0.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos407.27 million6.56 millionNot OptionableBCDABioCardia4010.94 million9.04 millionOptionableBLRXBioLineRx404.35 million4.30 millionOptionableDCOYDecoy Therapeutics20530,000530,000N/ADCOY, AIMD, BLRX, and BCDA HeadlinesRecent News About These CompaniesDecoy Therapeutics to Present at Two Peptide Therapeutics Conferences in BostonApril 27, 2026 | prnewswire.comDecoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development TranscriptApril 9, 2026 | seekingalpha.comDecoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral PipelineApril 9, 2026 | prnewswire.comDecoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026April 6, 2026 | prnewswire.comDecoy Therapeutics Regains Nasdaq Compliance After Reverse SplitApril 2, 2026 | tipranks.comDecoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 2, 2026 | prnewswire.comDecoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation PlatformMarch 11, 2026 | prnewswire.comDecoy Therapeutics, Inc: Decoy Therapeutics Announces 1-for-12 Reverse Stock SplitMarch 6, 2026 | finanznachrichten.deDecoy Therapeutics Announces Reverse Stock Split to Maintain ListingMarch 5, 2026 | tipranks.comDecoy Therapeutics Announces 1-for-12 Reverse Stock SplitMarch 5, 2026 | prnewswire.comDecoy Therapeutics Shareholders Approve Plan and Reverse SplitFebruary 25, 2026 | tipranks.comDecoy Therapeutics Joins Webull Corporate Connect Service PlatformFebruary 11, 2026 | prnewswire.comDecoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialFebruary 5, 2026 | prnewswire.comDecoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment AgreementFebruary 4, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, AIMD, BLRX, and BCDA Company DescriptionsAinos NASDAQ:AIMD$1.72 -0.01 (-0.29%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioCardia NASDAQ:BCDA$1.12 +0.03 (+2.27%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BioLineRx NASDAQ:BLRX$3.43 +0.39 (+12.93%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Decoy Therapeutics NASDAQ:DCOY$5.77 -0.07 (-1.16%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
